These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 18495823)

  • 1. Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations.
    Yazici Y; Adler NM; Yazici H
    Rheumatology (Oxford); 2008 Jul; 47(7):1054-7. PubMed ID: 18495823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of underpowered randomized clinical trials in rheumatology.
    Keen HI; Pile K; Hill CL
    J Rheumatol; 2005 Nov; 32(11):2083-8. PubMed ID: 16265683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.
    Bedard PL; Krzyzanowska MK; Pintilie M; Tannock IF
    J Clin Oncol; 2007 Aug; 25(23):3482-7. PubMed ID: 17687153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety reporting in randomized clinical trials - a need for improvement.
    Yazici Y
    Bull NYU Hosp Jt Dis; 2009; 67(2):209-10. PubMed ID: 19583556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some concerns about adverse event reporting in randomized clinical trials.
    Yazici Y
    Bull NYU Hosp Jt Dis; 2008; 66(2):143-5. PubMed ID: 18537786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries.
    Nasir A; Greenberg JD
    Bull NYU Hosp Jt Dis; 2007; 65(3):178-81. PubMed ID: 17922666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing quality of reports on randomized clinical trials in nursing journals.
    Parent N; Hanley JA
    Can J Cardiovasc Nurs; 2009; 19(2):25-39. PubMed ID: 19517902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements.
    Hernández AV; Steyerberg EW; Habbema JD
    J Clin Epidemiol; 2004 May; 57(5):454-60. PubMed ID: 15196615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
    Leombruno JP; Einarson TR; Keystone EC
    Ann Rheum Dis; 2009 Jul; 68(7):1136-45. PubMed ID: 18753157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitors.
    Yazici Y; Yazici H
    Ann Rheum Dis; 2007 Jan; 66(1):124-7. PubMed ID: 16831828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials.
    Yuen SY; Pope JE
    Rheumatology (Oxford); 2008 Sep; 47(9):1367-72. PubMed ID: 18577549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple sample size formula for analysis of covariance in randomized clinical trials.
    Borm GF; Fransen J; Lemmens WA
    J Clin Epidemiol; 2007 Dec; 60(12):1234-8. PubMed ID: 17998077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample-size calculations for studies with correlated ordinal outcomes.
    Kim HY; Williamson JM; Lyles CM
    Stat Med; 2005 Oct; 24(19):2977-87. PubMed ID: 16149125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Published randomized controlled trials of drug therapy for dementia often lack complete data on harm.
    Lee PE; Fischer HD; Rochon PA; Gill SS; Herrmann N; Bell CM; Sykora K; Anderson GM
    J Clin Epidemiol; 2008 Nov; 61(11):1152-60. PubMed ID: 18619812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How many do I need? Basic principles of sample size estimation.
    Devane D; Begley CM; Clarke M
    J Adv Nurs; 2004 Aug; 47(3):297-302. PubMed ID: 15238124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled trials in otolaryngology journals.
    Yao F; Singer M; Rosenfeld RM
    Otolaryngol Head Neck Surg; 2007 Oct; 137(4):539-44. PubMed ID: 17903567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
    Ferri C; Ferraccioli G; Ferrari D; Galeazzi M; Lapadula G; Montecucco C; Triolo G; Valentini G; Valesini G;
    J Rheumatol; 2008 Oct; 35(10):1944-9. PubMed ID: 18688917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An investigation of clinical studies suggests those with multiple objectives should have at least 90% power for each endpoint.
    Borm GF; Houben RM; Welsing PM; Zielhuis GA
    J Clin Epidemiol; 2006 Jan; 59(1):1-6. PubMed ID: 16360554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
    Mariette X
    Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.